Introduction

Platelets play a crucial role in maintaining normal blood conditions and forming thrombi (blood clots). The production and aggregation of platelets are central to the development of arterial ischaemic conditions such as coronary artery disease, cerebrovascular accidents, and peripheral arterial disease. Consequently, antiplatelet therapy is vital for preventing recurrent medical crises in individuals affected by these conditions.

While antiplatelet therapy lowers the risk of major vascular events in those with occlusive vascular disease (blocked blood vessels), it may elevate the risk of intracranial haemorrhage (bleeding in the brain). Consequently, managing antiplatelet therapy properly and effectively can be challenging and complex.^1,2

Uses of antiplatelet therapy

Antiplatelet therapy is used for a range of conditions, including:

• Acute coronary syndrome
• Post-percutaneous coronary intervention (PCI) with stenting
• Mechanical heart valves in combination with warfarin
• Acute ischaemic stroke
• Post-percutaneous intervention of peripheral arterial disease
• Device closure of an atrial septal defect (ASD) 
• Stable angina
• Coronary artery bypass grafting surgery
• Essential thrombocytosis
• Primary prevention of coronary artery disease
• Prevention of colon cancer
• Kawasaki disease
• Acute rheumatic disease
• Post-patent ductus arteriosus (PDA) device closure 
• Acute pericarditis
• Atrial fibrillation with a high risk of stroke
• Primary prevention of venous thromboembolism

Types of antiplatelet medication and their side effects

Types of antiplatelet medication

1. Aspirin
2. Clopidogrel 
3. Prasugrel
4. Ticagrelor²

Common side effects 

The following represent the most frequent undesirable outcomes linked to antiplatelet drugs:²

• Asthma triggered by aspirin
• Formation of nasal polyps 
• Chronic gastritis leading to upper gastrointestinal bleeding
• Appearance of ecchymosis (bruises)
• Haematuria (blood in the urine)
• Nosebleeds
• Dyspnea (shortness of breath)
• Haemorrhaging (bleeding) incidents
• Development of thrombocytopenia (low platelet count)
• Headache
• Nausea
• Diarrhea
• Pain
• Infection
• Upper respiratory symptoms
• Heart palpitations and/or arrhythmias
• Peripheral oedema (linked to cilostazol) 

Monitoring and management of side effects

Monitoring and addressing the side effects linked to antiplatelet therapy is vital for maintaining the treatment's safety and effectiveness. Regular medical check-ups, including physical examinations and blood tests like complete blood count (CBC) and platelet function tests, are imperative. 

A tailored approach is essential, and the patient's medical history, overall health, and response to the medication should all be considered. Honest and frequent communication between patients and healthcare providers is crucial. Patients should promptly report any unusual symptoms or side effects they experience.

Management of gastrointestinal effects, such as bleeding or stomach upset, may require doctors to adjust the dosage given or add gastroprotective agents to a patient’s regime. Addressing allergic reactions, evaluating bleeding risk, and educating patients about potential side effects form integral components of care. 

Healthcare providers should have emergency procedures for severe reactions, and continuously assess the long-term benefits and risks of antiplatelet therapy to ensure its ongoing suitability for patients. In essence, a collaborative and proactive strategy is vital for optimising the advantages of antiplatelet therapy while mitigating potential risks.

Precautions and contraindications

Antiplatelet agents are contraindicated in certain conditions and circumstances to ensure patient safety. These contraindications include:

• Large oesophageal varices
• Recent stroke: if a patient has had a stroke within the last two years, their use of antiplatelet agents is contraindicated
• History of intracranial haemorrhage: individuals with a history of intracranial bleeding within the skull are advised against using antiplatelet medications
• Marked thrombocytopenia: those with marked thrombocytopenia (which causes significantly low platelet counts) should not use antiplatelet medications
• Recent major surgery: antiplatelet agents should not be administered within 72 hours following major surgical procedures
• Hypersensitivity: individuals with a known hypersensitivity or allergic reaction to antiplatelet medications should avoid using them
• Acute bleeding: patients who experience ongoing instances of acute, clinically significant bleeding should not take antiplatelet agents
• End-stage renal disease: patients in end-stage renal disease and requiring haemodialysis should not take antiplatelet therapy
• Decompensated liver cirrhosis: individuals with liver cirrhosis (severely impaired liver function) should avoid antiplatelet agents
• Severe hypertension: antiplatelet agents are contraindicated in cases of severe hypertension (where blood pressure levels exceed 200/110 mmHg)
• Congestive heart failure (cilostazol only): the use of the antiplatelet drug cilostazol is contraindicated in individuals with congestive heart failure

Adhering to these contraindications is crucial to prevent adverse effects and complications associated with antiplatelet therapy. It is essential for healthcare providers to thoroughly assess patient medical histories and conditions before prescribing such medications.³

Patient education 

Ensuring patients are well-informed about antiplatelet therapy and its potential side effects is crucial for ensuring their adherence to their treatment regime and their well-being. This education should cover a thorough understanding of the prescribed medication, including its name, dosage, and how to take it.

Patients should be knowledgeable about common side effects, such as gastrointestinal discomfort or an increased risk of bleeding, with a particular emphasis on reporting any unusual symptoms promptly. Guidance on taking the medication with food, monitoring for allergic reactions, and strictly adhering to the prescribed schedule is essential. Patients should also understand the importance of regular medical check-ups, blood tests, and maintaining open communication with healthcare providers.

Clear information on emergency procedures, including when to seek immediate medical attention, is necessary. Additionally, discussions on potential interactions with other medications, long-term treatment perspectives, and incorporating a healthy lifestyle empower patients to actively engage in their care. Providing written materials and reliable online resources enhances patients' access to information and support related to their antiplatelet therapy.

Summary

In conclusion, effective management of antiplatelet therapy is crucial - requiring doctors to consider the delicate balance between preventing arterial ischaemic events and the potential risk of intracranial haemorrhage. The broad range of indications for antiplatelet medications, spanning from acute coronary syndrome to primary prevention of venous thromboembolism, underscores their vital role in medicine. Nevertheless, a comprehension of their common side effects, such as aspirin-induced asthma or ticagrelor-related dyspnea, requires vigilant monitoring and tailored interventions.

Proactive monitoring and management of side effects are fundamental for ensuring the safety and efficacy of antiplatelet therapy. Regular medical check-ups, comprehensive blood tests, and transparent communication between healthcare providers and patients constitute the cornerstone of this approach. Addressing potential complications, like gastrointestinal effects or allergic reactions, demands personalised adjustments in dosage or the incorporation of additional protective measures.

The precautions and contraindications associated with antiplatelet agents underscore the critical importance of individualised patient assessment. Adhering to contraindications, such as large oesophageal varices or recent major surgery, is imperative to prevent adverse effects. Patient education emerges as a pivotal element in this context, empowering individuals to actively engage in their care. From understanding medication names and dosages to recognising common side effects and knowing when to seek immediate medical attention, well-informed patients significantly contribute to the success of antiplatelet therapy.

The collaborative efforts of healthcare providers and patients, guided by a thorough understanding of indications, side effects, and precautions, establish a framework for optimising the benefits of antiplatelet therapy while minimising its potential risks. Embracing a holistic approach that encompasses monitoring, management, and patient education allows the medical community to navigate the complexities of antiplatelet therapy, fostering improved outcomes for individuals confronting various cardiovascular and thrombotic challenges.